Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name 4r,6r-dorzolamide
Drug ID BADD_D00006
Description Dorzolamide is a non-bacteriostatic sulfonamide derivative [A1304] and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension.[L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes.[A1303] Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects.[A1304] First marketed in 1995,[A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or in combination with [timolol] as Cosopt PF.[L11380]
Indications and Usage For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Also used prophylatically for the inhibition of perioperative IOP increase (before neodynium yttrium aluminum garnet laser posterior capsulotomy).
Marketing Status Prescription; Discontinued
ATC Code S01EC03
DrugBank ID DB00869
KEGG ID D07871
MeSH ID C062765
PubChem ID 92087
TTD Drug ID D05UYW
NDC Product Code 14445-404; 70377-081
Synonyms dorzolamide | 4-ethylamino-5,6-dihydro-6-methyl-7,7-dioxide-4H-thieno(2,3-b)thiopyran-2-sulfonamide | 5,6-dihydro-4-ethylamino-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide | dorzolamide, (trans)-isomer | Dorzolamide Chibret | MK 507 | MK-507 | Trusopt | dorzolamide hydrochloride | L 671152 | L-671,152
Chemical Information
Molecular Formula C10H16N2O4S3
CAS Registry Number 120279-89-2
SMILES CCNC1CC(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Choroidal detachment06.09.01.003; 12.01.04.006--Not Available
Colitis ischaemic07.08.01.004; 24.04.08.012--Not Available
Confusional state17.02.03.005; 19.13.01.001--
Conjunctival follicles06.06.02.002--Not Available
Conjunctival oedema06.04.01.001--Not Available
Conjunctivitis06.04.01.002; 11.01.06.012--
Corneal erosion06.06.03.003--Not Available
Cough22.02.03.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis contact10.01.01.003; 12.03.01.040; 23.03.04.004--Not Available
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.005--Not Available
Discomfort08.01.08.003--Not Available
Disorientation17.02.05.015; 19.13.01.002--Not Available
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.007--
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyspepsia07.01.02.001--
Dyspnoea02.01.03.002; 22.02.01.004--
Dysuria20.02.02.002--
Epistaxis22.04.03.001; 24.07.01.005--
Erythema multiforme10.01.03.015; 23.03.01.003--
Erythema of eyelid06.04.04.003; 23.03.06.006--Not Available
Eye discharge06.04.05.001--Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Eyelid oedema06.04.04.004; 10.01.05.001; 23.04.01.003--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages